Supernus Pharma (SUPN) Misses Q3 EPS by 31c

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of ($0.29), $0.31 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $153.88 million versus the consensus estimate of $144.94 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AeroVironment restates quarterly financials, citing $89M goodwill error
• Robinhood prices $2B convertible notes offering due 2029